Table 1 Clinical significance of MDSCs in lung cancer

[14]

CD11b⁺CD14⁻CD15⁺CD33⁺

PB

Advanced NSCLC

Decreased in the advanced-stage patients who had clinical benefit (PR or SD) and in the early-stage patients after removal of tumor.

[15]

CD11b⁺CD14⁺S100A9⁺

PB

Advanced NSCLC

Poor chemotherapy response and short PFS

[16]

CD16^lowCD11b⁺CD14⁻HLA-DR⁻CD15⁺CD33⁺

PB

Advanced NSCLC

Significantly increased compared to healthy controls

[17]

CD14⁺HLA-DR^−/low

PB

NSCLC

Negatively correlated with PFS

[18]

CD14⁺HLA-DR^−/low

PB

SCLC

Independent biomarker for poor prognosis

[19]

B7-H3⁺CD14⁺HLA-DR^−/low

PB

NSCLC

Decreased RFS

[20]

CD11b⁺CD14⁻HLA-DR⁻CD33⁺CD15⁺ ILT3^high

PB

Stage IV

NSCLC

Decreased OS

[21]

lin⁻CD14⁻CD11b⁺ CD39⁺/CD73⁺PMN-MDSCs

lin⁻CD14⁺CD11b⁺ CD39⁺/CD73⁺M-MDSCs

PB

NSCLC

Decreased with chemotherapy cycles in SD and PR groups, increased in PD group.

[22]

Lin⁻CD14⁺CD15⁺CD11b⁺ CD33 ⁺HLA-DR⁻

PB

NSCLC

Independent prognostic marker for decreased PFS and OS.

[23]

Lin⁻CD14⁻HLA-DR⁻

PB

NSCLC

After three cycles, bevacizumab-based chemotherapy significantly reduced the level of Lin⁻CD14⁻HLA-DR⁻ cells.

[24]

Lox-1⁺ PMN-MDSCs

PB

NSCLC

Patients with a higher ratio of Tregs to Lox-1⁺PMN-MDSCs in the blood after the 1st nivolumab had better PFS.

[25]

Lin⁻CD33 ⁺ CD14⁺ CD15⁻ HLA-DR⁻

PB

Metastatic NSCLC

Decreased OS in anti-PD-1 treatment.

[26]

SSC^lowLin⁻HLA-DR^−/LOWCD33⁺ CD13⁺CD11b⁺CD15⁺CD14⁻

PB

stage IIIB or IV NSCLC

PMN-MDSCs (≥6 cell/μl) showed a significantly improved survival in anti-PD-1 treatment.

[27]

CD33⁺CD11b⁺CD14⁻ PMN-MDSCs CD33⁺CD11b⁺CD14⁺HLA-DR^−/low M-MDSCs

PB

NSCLC

Both subtypes decreased after SBRT treatment.

[28]

CD11b⁺HLA-DR^−/lowCD14⁻CD15⁺ PMN-MDSCs

CCR5⁺HLA-DR^−/lowCD11b⁺CD14⁺CD15⁻ M-MDSCs

TT and PB

Resectable NSCLC

TT PMN-MDSCs displayed higher PD-L1 expression levels than the same cells in the PB.

Significant correlations between lower total PMN-MDSCs and CCR5⁺ M-MDSCs frequencies in the peripheral blood and improved RFS.